146 related articles for article (PubMed ID: 17640957)
1. Haplotypes and a novel defective allele of CES2 found in a Japanese population.
Kim SR; Sai K; Tanaka-Kagawa T; Jinno H; Ozawa S; Kaniwa N; Saito Y; Akasawa A; Matsumoto K; Saito H; Kamatani N; Shirao K; Yamamoto N; Yoshida T; Minami H; Ohtsu A; Saijo N; Sawada J
Drug Metab Dispos; 2007 Oct; 35(10):1865-72. PubMed ID: 17640957
[TBL] [Abstract][Full Text] [Related]
2. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2).
Kubo T; Kim SR; Sai K; Saito Y; Nakajima T; Matsumoto K; Saito H; Shirao K; Yamamoto N; Minami H; Ohtsu A; Yoshida T; Saijo N; Ohno Y; Ozawa S; Sawada J
Drug Metab Dispos; 2005 Oct; 33(10):1482-7. PubMed ID: 16033949
[TBL] [Abstract][Full Text] [Related]
3. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene.
Wu MH; Chen P; Wu X; Liu W; Strom S; Das S; Cook EH; Rosner GL; Dolan ME
Pharmacogenetics; 2004 Sep; 14(9):595-605. PubMed ID: 15475733
[TBL] [Abstract][Full Text] [Related]
4. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Fukushima-Uesaka H; Kurose K; Kaniwa N; Kamatani N; Shirao K; Yamamoto N; Hamaguchi T; Kunitoh H; Ohe Y; Tamura T; Yamada Y; Minami H; Ohtsu A; Yoshida T; Saijo N; Sawada J
Cancer Chemother Pharmacol; 2008 Aug; 62(3):529-37. PubMed ID: 17992531
[TBL] [Abstract][Full Text] [Related]
6. Expression and characterization of a human carboxylesterase 2 splice variant.
Schiel MA; Green SL; Davis WI; Sanghani PC; Bosron WF; Sanghani SP
J Pharmacol Exp Ther; 2007 Oct; 323(1):94-101. PubMed ID: 17636009
[TBL] [Abstract][Full Text] [Related]
7. Hydrolysis of irinotecan and its oxidative metabolites, 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin and 7-ethyl-10-[4-(1-piperidino)-1-amino]-carbonyloxycamptothecin, by human carboxylesterases CES1A1, CES2, and a newly expressed carboxylesterase isoenzyme, CES3.
Sanghani SP; Quinney SK; Fredenburg TB; Davis WI; Murry DJ; Bosron WF
Drug Metab Dispos; 2004 May; 32(5):505-11. PubMed ID: 15100172
[TBL] [Abstract][Full Text] [Related]
8. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
Minami H; Sai K; Saeki M; Saito Y; Ozawa S; Suzuki K; Kaniwa N; Sawada J; Hamaguchi T; Yamamoto N; Shirao K; Yamada Y; Ohmatsu H; Kubota K; Yoshida T; Ohtsu A; Saijo N
Pharmacogenet Genomics; 2007 Jul; 17(7):497-504. PubMed ID: 17558305
[TBL] [Abstract][Full Text] [Related]
9. Enzyme-prodrug systems: carboxylesterase/CPT-11.
Danks MK; Potter PM
Methods Mol Med; 2004; 90():247-62. PubMed ID: 14657567
[No Abstract] [Full Text] [Related]
10. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C> T (P229L) found in an African-American.
Kaniwa N; Kurose K; Jinno H; Tanaka-Kagawa T; Saito Y; Saeki M; Sawada J; Tohkin M; Hasegawa R
Drug Metab Dispos; 2005 Mar; 33(3):458-65. PubMed ID: 15572581
[TBL] [Abstract][Full Text] [Related]
11. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.
Bellott R; Le Morvan V; Charasson V; Laurand A; Colotte M; Zanger UM; Klein K; Smith D; Bonnet J; Robert J
Cancer Chemother Pharmacol; 2008 Mar; 61(3):481-8. PubMed ID: 17483951
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan.
Ando Y; Ueoka H; Sugiyama T; Ichiki M; Shimokata K; Hasegawa Y
Ther Drug Monit; 2002 Feb; 24(1):111-6. PubMed ID: 11805731
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials.
Rivory LP; Haaz MC; Canal P; Lokiec F; Armand JP; Robert J
Clin Cancer Res; 1997 Aug; 3(8):1261-6. PubMed ID: 9815808
[TBL] [Abstract][Full Text] [Related]
14. Modulation of irinotecan metabolism by ketoconazole.
Kehrer DF; Mathijssen RH; Verweij J; de Bruijn P; Sparreboom A
J Clin Oncol; 2002 Jul; 20(14):3122-9. PubMed ID: 12118026
[TBL] [Abstract][Full Text] [Related]
15. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase.
Morton CL; Wierdl M; Oliver L; Ma MK; Danks MK; Stewart CF; Eiseman JL; Potter PM
Cancer Res; 2000 Aug; 60(15):4206-10. PubMed ID: 10945631
[TBL] [Abstract][Full Text] [Related]
16. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
[TBL] [Abstract][Full Text] [Related]
17. Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
Saito Y; Sai K; Maekawa K; Kaniwa N; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Ohe Y; Yamada Y; Tamura T; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Sawada J
Drug Metab Dispos; 2009 Feb; 37(2):272-6. PubMed ID: 18981166
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38.
Mathijssen RH; Verweij J; Loos WJ; de Bruijn P; Nooter K; Sparreboom A
Br J Cancer; 2002 Jul; 87(2):144-50. PubMed ID: 12107833
[TBL] [Abstract][Full Text] [Related]
19. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer.
Sai K; Saeki M; Saito Y; Ozawa S; Katori N; Jinno H; Hasegawa R; Kaniwa N; Sawada J; Komamura K; Ueno K; Kamakura S; Kitakaze M; Kitamura Y; Kamatani N; Minami H; Ohtsu A; Shirao K; Yoshida T; Saijo N
Clin Pharmacol Ther; 2004 Jun; 75(6):501-15. PubMed ID: 15179405
[TBL] [Abstract][Full Text] [Related]
20. Involvement of up-regulation of hepatic breast cancer resistance protein in decreased plasma concentration of 7-ethyl-10-hydroxycamptothecin (SN-38) by coadministration of S-1 in rats.
Yokoo K; Hamada A; Watanabe H; Matsuzaki T; Imai T; Fujimoto H; Masa K; Imai T; Saito H
Drug Metab Dispos; 2007 Sep; 35(9):1511-7. PubMed ID: 17537871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]